No Data
No Data
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
Shareholders in Exact Sciences (NASDAQ:EXAS) Have Lost 54%, as Stock Drops 4.8% This Past Week
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Exact Sciences Corporation (NASDAQ:EXAS) have had an unfortunate run in the last three years. Regre
Buy Rating Affirmed for Exact Sciences Amid Market Expansion and Product Advancement Prospects
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)
The New England Journal of Medicine Publishes Cologuard Plus Test Results From Pivotal BLUE-C Study
Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included 98 colorectal cancers
Bio-Techne and Qiagen Had the Biggest Increase in Short Interest Levels Last Month - Baird
No Data